Funding for this research was provided by:
Instituto de Investigación Sanitaria y Biomédica de Alicante-ISABIAL (UGP-16-156)
Text and Data Mining valid from 2018-03-22
Received: 26 October 2017
Accepted: 6 March 2018
First Online: 22 March 2018
Ethics approval and consent to participate
: The ethics committee of the Hospital General Universitario de Alicante (2017/05 act) and the Spanish drugs regulatory administration approved this study; according to these organisations, informed consent was not necessary due to the retrospective nature of the study.
: Not applicable.
: MA has received speaking and advisory fees from Menarini, Astra-Zeneca, Horizon, and Grünenthal. The other authors declare no conflicts of interest in the conduct of the present study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.